<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734718</url>
  </required_header>
  <id_info>
    <org_study_id>GIPHOT</org_study_id>
    <secondary_id>H-18015379</secondary_id>
    <nct_id>NCT03734718</nct_id>
  </id_info>
  <brief_title>The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes</brief_title>
  <official_title>The Role of Glucose-dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present project the investigators will evaluate whether glucagonotropic properties of
      the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be
      utilized as a safeguard against hypoglycemia in the daily life of participants with type 1
      Diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, double-blinded, cross-over study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The peptides/placebo is prepared, in a randomized fashion, by a laboratory assistant.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>an average of 6 days</time_frame>
    <description>Time spent in hypoglycemia, near-normoglycemia and hyperglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin hormones</measure>
    <time_frame>Evaluated at experimental day 0,1 and 6 of each intervention</time_frame>
    <description>Incretin hormones GLP-1 and GIP. Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids (FFA)</measure>
    <time_frame>Evaluated at experimental day 0,1 and 6 of each intervention</time_frame>
    <description>Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mRNA</measure>
    <time_frame>At day 6, and 10 of the study</time_frame>
    <description>mRNA analysis of fat biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Protein content</measure>
    <time_frame>Evaluated at experimental day 0,1 and 6 of each intervention</time_frame>
    <description>Protein analysis of fat biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>The first 24 hours of intervention and at experimental day 6</time_frame>
    <description>Changes in blood pressure, mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>The first 24 hours of intervention and at experimental day 6</time_frame>
    <description>Changes in pulse, beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose regulatory hormones</measure>
    <time_frame>Evaluated at experimental day 0,1 and 6 of each intervention</time_frame>
    <description>Counter regulatory hormones: glucagon, noradrenalin, cortisol, somatotropin, and insulin/c-peptide. Incremental and total area under the Concentration-Time Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic hypoglycemic events</measure>
    <time_frame>An average of 1 week</time_frame>
    <description>Self-reported events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Glucose-Dependent Insulinotropic Polypeptide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>Infusion of Glucose-dependent insulinotropic peptide</description>
    <arm_group_label>Glucose-Dependent Insulinotropic Polypeptide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 20 and 27 kg/m2

          -  T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c
             &lt;69 mmol/mol (&lt;8.5%)

          -  Treatment with a stable insulin regimen ≥3 months

          -  T1D duration between 2 and 15years

          -  C-peptide negative (C-peptide ≤ 16 ng/ml)

          -  Informed consent

        Exclusion Criteria:

          -  Anemia (hemoglobin outside normal range)

          -  Known liver disease and/or ALAT and/or ASAT &gt; 2 times normal values

          -  Estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73 m2 or albuminuria

          -  Prior Cardiovascular events and/or abnormal heart rate/blood pressure

          -  Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs
             affecting glucose metabolism during the study period or within 30 days prior to
             randomization

          -  Any physical or psychological condition that the investigator feels would interfere
             with trial participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Caucasian men</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center CopenhagenSteno Diabetes Center Copenhagen, Clinical Metabolic Physiology</name>
      <address>
        <city>Hellerup</city>
        <zip>2800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Inhibitory Polypeptide</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Incretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

